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ABSTRACT
Reinfection by the severe acute respiratory syndrome coronavirus type 2 (SARS-COV-2) 
has been reported in many countries, suggesting that the virus may continue to circulate 
among humans despite the possibility of local herd immunity due to massive previous 
infections. The emergence of variants of concern (VOC) that are more transmissible than 
the previous circulating ones has raised particular concerns on the vaccines effectiveness 
and reinfection rates. The P.1 lineage was first identified in December 2020 in Manaus city 
and is now globally spread. We report the first case of reinfection of SARS-CoV-2 caused 
by the P.1 variant outside of Manaus. The potential of these new variants to escape naturally 
and vaccine- induced immunity highlights the need for a global vigilance.
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INTRODUCTION
As of March 2021, the coronavirus disease 2019 (COVID-19) pandemic caused 
by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has 
resulted in over 118 million cases and 2.7 million deaths worldwide1. The absence 
of pre-existent immunity against SARS-CoV-2 could be one of the factors associated 
with its rapid global spread. Previous studies suggest that immunoglobulin G (IgG) 
antibodies against SARS-CoV-2 generated post-infection are associated with around 
80% protection from reinfection for at least six months2-4. Since the beginning of 
the pandemic, concerns on the possibility of reinfection have been raised. However, 
detection of reinfection is challenging and so far few reinfection cases caused by 
phylogenetically distinct lineages have been described5, suggesting that reinfection 
is a rare event. More recently, the emergence of new variants of concern (VOC), 
such as B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil) that rapidly spread 
and may escape from neutralizing antibodies6,7 complicates matters further. Here we 
describe a symptomatic case of SARS-CoV-2 reinfection caused by the P.1 lineage. 
CASE DESCRIPTION
We present a case of SARS-CoV-2 reinfection in a 26-year-old woman, resident 
of Araraquara city, Sao Paulo State, Brazil. The patient reported having rheumatism 
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but had never received any specific treatment. In the first 
infection episode, the patient sought the public health system 
for COVID-19 testing on September 29, 2020 (Figure 1A). 
The patient reported symptoms consistent with COVID-19 
(Figure 1A and 1C) since September 25, 2020, and reported 
that her husband tested positive for SARS-CoV-2 by 
real-time quantitative reverse transcription-polymerase 
chain reaction (RT-qPCR) six days before. After 24h, 
her COVID-19 diagnosis was confirmed by RT-qPCR. 
The mild-COVID-19 was completely resolved during the 
isolation period, and no hospitalization was required. 
Then, in early February, 2021, she reported similar 
symptoms described in the COVID-19 episode in September 
2020 with joint pain in the right leg in addition to difficulty 
breathing (Figure 1C). Two days later, her co-worker was 
also diagnosed with COVID-19, and all employees of 
the company were required to perform the RT-qPCR. On 
February 4, 2021, her reinfection was confirmed by means 
of SARS-CoV-2 RNA detection in a nasopharyngeal swab 
sample by RT-qPCR (Figure 1A). Similar to the previous 
SARS-CoV-2 episode, she presented only with mild 
symptoms and hospitalization was again not required. 
However, this time the patient reported persisting symptoms 
even two weeks after the second episode, including 
tiredness, dizziness and fatigue. 
Samples from her two SARS-CoV-2 episodes were sent 
to the Institute of Tropical Medicine at the University of Sao 
Paulo to confirm the molecular diagnosis and to perform the 
whole virus genome sequencing. Samples were submitted 
to a RT-qPCR protocol that is able to differentiate between 
VOC and non-VOC viruses8. The results indicated that the 
first infection in September 2020 was caused by a non-VOC 
virus. This is expected as the two currently circulating VOCs 
in Brazil (B.1.1.7 and P.1) had not emerged yet6,9. However, 
the RT-qPCR results suggested that the second episode was 
caused by a VOC, that could be either B.1.1.7 or P.1. The 
cycle threshold (CT) values of the VOC RT-qPCR were 21 
and 24 for the samples from the first and second episode, 
respectively. 
RNA from the second episode was submitted to 
SARS-CoV-2 complete genome sequencing using 
the MinION sequencing platform (Oxford Nanopore 
Technologies, ONT, UK) as previously described10. 
Unfortunately, the first sample was exhausted during RT-PCR 
protocols. The SARS-CoV-2 sequencing covered 83% of 
the whole virus genome (20-fold coverage) and according 
Figure 1 - The context of the two episodes of SARS-CoV-2 infection: A) Time line of the COVID-19 first and second episodes; B) 
Cumulative number of cases in Araraquara city from August, 2020 to March, 2021. Red arrows correspond to the patient’s COVID-19 
episodes. The dotted line highlights the first detection of the P.1 lineage in Araraquara city; C) Description of the symptoms reported 
by the patient during the first and the second episodes.
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to Pangolin it was classified as P.1 lineage11. The SARS-
CoV-2 complete genome generated in this study is available 
at GISAID under ID EPI_ISL_1004238. To contextualize 
the virus isolated from the second infection, a maximum 
likelihood (ML) phylogenetic tree was constructed with 
PhyML v.3.012 using as reference viruses from P.1 lineage 
(Manaus, Araraquara and Sao Paulo city) and the parent 
lineage B.1.1.28. According to the ML tree, the virus from 
the second infection of this case report clustered within 
a monophyletic cluster of P.1 viruses (Figure 2). Finally, 
the patient’s serum was collected in March 19, 2021 and a 
serological assay for anti-SARS-COV-2 IgG detection was 
performed (Euroimmun Anti-SARS-CoV-2 ELISA Assay, 
Lübeck, Germany). The result was positive and the antibody 
detected was of high avidity as determined by the urea 6M 
treatment performed right after the ELISA test.
DISCUSSION
We report here the first case of SARS-CoV-2 reinfection 
caused by the P.1 lineage outside of Manaus13. The P.1 
lineage emerged in November, 2020 in Manaus city, and 
spread fast, causing the prevalence to increase from 25% 
to almost 90% in one month6. Later on, the P.1 lineage 
was detected in several Brazilian States and 45 countries 
around the world14. In Sao Paulo State, the P.1 lineage 
was first described in Araraquara city, in late January, 
2021, during a dramatic increase in the number of cases 
and hospitalizations (Figure 1B). One month later, 
Araraquara’s health system reached its limits and the P.1 
lineage was responsible for >95% of all positive samples 
in the municipality (data not shown). Our finding supports 
that a natural SARS-CoV-2 infection may not necessarily 
prevent a secondary infection. As previous reported15,16, the 
secondary SARS-CoV-2 infection in the female patient did 
not present with increased severity of symptoms, except 
that in this case, some symptoms have persisted for more 
than 14 days. 
Based on in vitro studies, antibodies binding to the 
viral spike induced by vaccine or from human convalescent 
sera present with decreased neutralization capacity against 
the emerging SARS-CoV-2 variants7,17. Furthermore, 
detailed data on SARS-CoV-2 seroprevalence in Manaus 
city suggested that P.1 has a 25-61% capacity to evade 
the immunity elicited by a previous infection caused by 
non-P.1 viruses6. However, it is too premature to attribute 
this particular reinfection case to the ability of the new 
variants to subvert the immune system. To the best of 
our knowledge, the 31 SARS-CoV-2 reinfection episodes 
described so far (with the exception of Naveca et al.13 
and Graham et al.18) were caused by non-VOC viruses5, 
indicating that reinfection with P.1 evading immunity 
induced by the infection of previously circulating lineages 
is not a particularity of VOC. 
Reinfection is well known characteristic of coronaviruses, 
such as NL63 and 229E, for which the protection elicited by 
antibodies may last only six months to one year19. According 
to Bauer et al.20, the avidity of IgG towards SARS-CoV-2 
antigens is low for the majority of patients they tested, even 
several months after the disease. Here, the patient presented 
with high avidity IgG anti-SARS-CoV-2 a month after the 
second infection. Following this reasoning, we expected the 
patient to present with high avidity antibodies four months 
after the first episode, nevertheless, these antibodies were 
not able to prevent the second episode caused by the P.1 
lineage. 
The strategies used by SARS-CoV-2 to evade the immune 
responses remain unclear, and a better understanding on the 
Figure 2 - Maximum Likelihood (ML) phylogenetic tree of 38 
complete genomes from P.1 and B.1.1.28 SARS-CoV-2. The 
isolate of the patient from Araraquara city corresponding to the 
second infection (red dot) clustered within the well supported 
clade of P.1 viruses from Manaus, Araraquara and Sao Paulo 
(blue dots) retrieved from GISAID. Viruses belonging to the 
B.1.1.28 parent lineage are represented by dark red dots.
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quality and durability of cellular and humoral immunity 
elicited by natural infections with SARS-CoV-2 or vaccines 
are crucial. The emergence of variants with a repertoire 
of mutations in the spike protein highlights the need of 
quantitative assessments on the frequency of specific 
reinfection rates caused by SARS-CoV-2 variants. 
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